David Krige

David has 20 years’ experience leading oncology translational medicine programmes with companies including PsiOxus Therapeutics, Immunocore and Accession Therapeutics, a clinical stage viral immunotherapy company, where he is currently Chief Development Officer. David has a PhD in Biochemistry from the University of London.